title: Strategies in functional proteomics: Unveiling the pathways to precision oncology.
abstract: Personalised strategies in cancer care are required to overcome the therapeutic challenges posed by variability between patients and disease subsets. To this end, enhanced precision tools must be developed to describe the molecular drivers of malignant proliferation. Such tools must also identify druggable targets and biomarkers in order to provide essential information regarding drug development and therapeutic outcome. Here we discuss how proteomics-based approaches provide a set of viable methodologies capable of delivering quantitative information throughout the main stages of personalised oncology and a ratiometric platform that delivers systems-wide methods for drug evaluation.
authors: Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. Electronic address: r.favicchio@imperial.ac.uk.
authors: Rosy
authors: R
authors: Favicchio
authors: Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
authors: Chloe
authors: C
authors: Thepaut
authors: Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
authors: Hua
authors: H
authors: Zhang
authors: Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
authors: Richard
authors: R
authors: Arends
authors: Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
authors: Justin
authors: J
authors: Stebbing
authors: Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton BN1 9QG, UK. Electronic address: g.giamas@sussex.ac.uk.
authors: Georgios
authors: G
authors: Giamas
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D019295:Computational Biology; D030562:Databases, Protein; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D025202:Molecular Diagnostic Techniques; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism*; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D018579:Patient Selection; D057285:Precision Medicine / Q000379:methods*; D011237:Predictive Value of Tests; D060066:Protein Interaction Maps; D040901:Proteomics / Q000379:methods*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins
keywords: Biomarkers; Cancer drivers; Drug development; Personalised oncology; Proteomics; Therapeutics